| abstract |
The present invention discloses crystalline Polymorphic Form I of compound 5-(3,5- dimethylphenoxy-) methyl)-2-oxazolidinone, characterized by x-ray diffraction pattern having peaks at 10.355, 14.285,18.625, 19.030, 20.810 and 22.475± 0.30 degrees 2 theta angle, and melting point ranging from 122.50C to 1240C which is characterized by Diffrencial Scanning Calorimetry. The present invention further discloses processes for the preparation thereof, pharmaceutical preparations comprising the said Polymorph and its use in the treatment of depression of central synaptic transmissions. |